Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.98 -4.3%	$2.88	$1.72 ▼ $381.10	$6.81M	5.64	125,551 shs	122,618 shs
ENTO Entero Therapeutics	$2.04 +0.5%	$1.49	$0.84 ▼ $2.78	$3.22M	0.8	5.23 million shs	163,315 shs
PKBO Peak Bio	$0.02	$0.05	$0.00 ▼ $0.26	$520K	1.75	8,940 shs	66,140 shs
TNFA TNF Pharmaceuticals	$0.06 -16.8%	$0.11	$0.06 ▼ $2.02	$1.07M	1.82	65.25 million shs	53.39 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	+5.61%	+1.47%	-33.87%	-62.42%	-99.98%
ENTO Entero Therapeutics	-1.46%	+10.33%	+36.81%	+78.12%	+61.11%
PKBO Peak Bio	0.00%	0.00%	0.00%	0.00%	+800.00%
TNFA TNF Pharmaceuticals	-20.86%	-26.59%	-29.81%	-56.94%	+7,509,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APVO Aptevo Therapeutics	3.2637 of 5 stars	3.5	5.0	0.0	0.0	2.5	0.0	1.3
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PKBO Peak Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APVO Aptevo Therapeutics	3.00	Buy	$219,040.00	11,062,526.26% Upside
ENTO Entero Therapeutics	0.00	N/A	N/A	N/A
PKBO Peak Bio	0.00	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APVO Aptevo Therapeutics	$3.11M	2.09	N/A	N/A	$1.98 per share	1.00
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	($3.96) per share	N/A
PKBO Peak Bio	$370K	1.41	N/A	N/A	($0.90) per share	-0.03
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APVO Aptevo Therapeutics	-$24.13M	N/A	0.00	N/A	N/A	N/A	-675.52%	-175.68%	11/5/2025 (Estimated)
ENTO Entero Therapeutics	-$18.06M	N/A	0.00	∞	N/A	N/A	-1,063.82%	-17.94%	N/A
PKBO Peak Bio	-$12.83M	-$0.16	N/A	∞	N/A	N/A	N/A	-179.31%	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$2.31	N/A	∞	N/A	N/A	-69.21%	-33.98%	N/A

Latest PKBO, APVO, TNFA, and ENTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	TNFA TNF Pharmaceuticals	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/14/2025	Q2 2025	ENTO Entero Therapeutics	N/A	-$0.42	N/A	-$0.21	N/A	N/A
8/11/2025	Q2 2025	APVO Aptevo Therapeutics	-$83.20	-$8.40	+$74.80	-$8.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	N/A
PKBO Peak Bio	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APVO Aptevo Therapeutics	N/A	2.27	2.27
ENTO Entero Therapeutics	N/A	2.81	2.90
PKBO Peak Bio	N/A	0.07	0.06
TNFA TNF Pharmaceuticals	N/A	0.93	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APVO Aptevo Therapeutics	8.06%
ENTO Entero Therapeutics	12.30%
PKBO Peak Bio	N/A
TNFA TNF Pharmaceuticals	9.64%

Insider Ownership

Company	Insider Ownership
APVO Aptevo Therapeutics	0.01%
ENTO Entero Therapeutics	0.75%
PKBO Peak Bio	19.90%
TNFA TNF Pharmaceuticals	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APVO Aptevo Therapeutics	50	3.29 million	756,000	Not Optionable
ENTO Entero Therapeutics	9	1.59 million	1.58 million	N/A
PKBO Peak Bio	3	23.13 million	18.52 million	Not Optionable
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A

PKBO, APVO, TNFA, and ENTO Headlines

Recent News About These Companies

TNF Pharmaceuticals announces improved financial position

August 20 at 3:02 AM | msn.com

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

August 19 at 5:20 PM | businesswire.com

TNF Pharmaceuticals Inc Ordinary Shares TNFA - Morningstar

July 11, 2025 | morningstar.comM

TNF Pharmaceuticals, Inc. (TNFA) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

June 25, 2025 | finance.yahoo.com

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules

May 9, 2025 | tipranks.com

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025 | businesswire.com

TNF Pharmaceuticals uses AI to refine patient selection for trials

April 24, 2025 | uk.investing.com

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

April 22, 2025 | finance.yahoo.com

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

April 22, 2025 | msn.com

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

April 17, 2025 | finance.yahoo.com

TNF Pharmaceuticals, Inc. Common Stock (TNFA) Short Interest

April 3, 2025 | nasdaq.com

TNF Pharmaceuticals faces Nasdaq delisting over price

March 23, 2025 | investing.com

TNF Pharmaceuticals, Inc. Common Stock

March 20, 2025 | fxempire.comF

TNF Pharmaceuticals shares R&D progress on Isomyosamine

March 12, 2025 | uk.investing.com

TNF Pharmaceuticals initiates isomyosamine trial

February 25, 2025 | markets.businessinsider.com

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

February 25, 2025 | businesswire.com

TNFA stock touches 52-week low at $0.48 amid market challenges

February 14, 2025 | msn.com

TNFA stock touches 52-week low at $1.02 amid market challenges

January 30, 2025 | msn.com

How Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?

January 30, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

PKBO, APVO, TNFA, and ENTO Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

$1.98 -0.09 (-4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$2.02 +0.04 (+1.77%)

As of 07:14 PM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Entero Therapeutics NASDAQ:ENTO

$2.04 +0.01 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.00 (+0.25%)

As of 07:51 PM Eastern

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Peak Bio NASDAQ:PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

TNF Pharmaceuticals NASDAQ:TNFA

$0.06 -0.01 (-16.78%)

Closing price 04:00 PM Eastern

Extended Trading

$0.07 +0.01 (+10.40%)

As of 07:59 PM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time